Welcome to our dedicated page for Rigel Pharmaceuticals (New) news (Ticker: RIGL), a resource for investors and traders seeking the latest updates and insights on Rigel Pharmaceuticals (New) stock.
Rigel Pharmaceuticals reports news on a commercial-stage biotechnology business focused on hematologic disorders and cancer. Company updates commonly cover sales of TAVALISSE (fostamatinib disodium hexahydrate), GAVRETO (pralsetinib) and REZLIDHIA (olutasidenib), along with contract revenue from collaborations and quarterly operating results.
Recurring developments also include clinical and regulatory updates for Rigel's pipeline, including R289 in lower-risk MDS, published clinical data involving GAVRETO, licensing and collaboration activity, board appointments, equity inducement grants and other governance matters tied to its Nasdaq-listed common stock.
Rigel Pharmaceuticals (Nasdaq: RIGL) announced the granting of 250,000 stock options to new EVP and Chief Commercial Officer David A. Santos, in accordance with NASDAQ Listing Rule 5635(c)(4). These options will vest over four years with a one-year cliff, alongside an additional 250,000 options contingent on future performance achievements. The exercise price aligns with Rigel's stock price on August 19, 2020. Rigel is focused on developing innovative small molecule drugs for immune and hematologic disorders, having FDA-approved TAVALISSE for chronic immune thrombocytopenia.
Rigel Pharmaceuticals (Nasdaq: RIGL) reported its Q2 2020 financial results, showing revenues of $16.0 million, a 47% increase from Q2 2019. The company reported a net loss of $17.6 million, narrowing from $20.6 million year-over-year. TAVALISSE sales growth continued as the drug became available in European markets. Rigel is advancing trials for TAVALISSE in COVID-19 pneumonia in collaboration with Imperial College London, leveraging its active metabolite R406, which shows promise in reducing inflammation in COVID-19 patients.
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) will disclose its second quarter 2020 financial results on August 4, 2020, after market close. Following the announcement, a live conference call will be held at 4:30pm ET to discuss the results and business updates. Interested participants can join by dialing (877) 407-3088 (domestic) or (201) 389-0927 (international). Rigel focuses on developing innovative small molecule drugs for immune and hematologic disorders. Their lead product, TAVALISSE, is approved for chronic immune thrombocytopenia.
On July 27, 2020, Rigel Pharmaceuticals (Nasdaq: RIGL) announced the publication of a post-hoc data analysis of TAVALISSE in the British Journal of Haematology. This analysis highlights a 78% response rate in adult patients with chronic immune thrombocytopenia (ITP) receiving TAVALISSE as a second-line therapy. Adverse events were manageable and consistent with previous reports. The findings suggest a potential shift in treatment paradigms, emphasizing the need for novel options in ITP management, as existing treatments are often insufficient for many patients.
Rigel Pharmaceuticals announced an investigator-sponsored trial (IST) by Imperial College London to assess the efficacy of fostamatinib, an oral SYK inhibitor, for treating COVID-19 pneumonia. Fostamatinib, marketed as TAVALISSE in the U.S., is FDA-approved for chronic immune thrombocytopenia. The trial aims to determine its effectiveness compared to ruxolitinib and standard care in preventing severe COVID-19 pneumonia. Initial studies suggest fostamatinib may inhibit inflammatory processes involved in the disease, providing hope for patients experiencing acute respiratory distress syndrome.